Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients

被引:7
|
作者
Virseda-Berdices, Ana [1 ,2 ]
Rojo, David [3 ]
Martinez, Isidoro [1 ,2 ]
Berenguer, Juan [2 ,4 ,5 ]
Gonzalez-Garcia, Juan [2 ,6 ,7 ]
Brochado-Kith, Oscar [1 ,2 ]
Fernandez-Rodriguez, Amanda [1 ,2 ]
Diez, Cristina [2 ,4 ,5 ]
Hontanon, Victor [2 ,6 ,7 ]
Perez-Latorre, Leire [2 ,4 ,5 ]
Mican, Rafael [2 ,6 ,7 ]
Barbas, Coral [3 ]
Resino, Salvador [1 ,2 ]
Jimenez-Sousa, Maria Angeles [1 ,2 ]
机构
[1] Inst Salud Carlos III ISCIII, Ctr Nacl Microbiol CNM, Unidad Infecc Viral & Inmunidad, Madrid, Spain
[2] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas, Madrid, Spain
[3] Univ CEU San Pablo, Fac Farm, Dept Quim & Bioquim, Ctr Metab & Bioanal CEMBIO,Urbanizac Monteprincip, Madrid 28925, Spain
[4] Hosp Gen Univ Gregorio Maranon, Unidad Enfermedades Infecciosas VIH, Madrid, Spain
[5] Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
[6] Hosp Univ La Paz, Serv Med Interna Unidad VIH, Madrid, Spain
[7] Inst Invest Sanitaria La Paz IdiPAZ, Madrid, Spain
关键词
Chronic hepatitis C; HIV; Cirrhosis; Metabolomics; DAAs therapy; HCV elimination; HUMAN-IMMUNODEFICIENCY-VIRUS; AMINO-ACID GRANULES; EVENT-FREE SURVIVAL; HEPATITIS-C; LIVER-DISEASE; HEPATOCELLULAR-CARCINOMA; PROGRESSION; SOFOSBUVIR; FIBROSIS;
D O I
10.1016/j.biopha.2022.112623
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: A better understanding of the evolution of cirrhosis after hepatitis C virus (HCV) clearance is essential since the reversal of liver injury may not happen. We aimed to assess the evolution of plasma metabolites after direct-acting antivirals (DAAs) therapy and their association with liver disease scores in HIV/HCV-coinfected patients with advanced HCV-related cirrhosis. Methods: We performed a prospective study in 49 cirrhotic patients who started DAAs therapy. Data and samples were collected at baseline and 36 weeks after SVR. Metabolomics analysis was carried out using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Inflammation-related biomarkers were analyzed using ProcartaPlex Immunoassays. Results: At 36 weeks after SVR, patients experienced significant decrease in taurocholic acid, 2,3-butanediol, and LPC(18:0); while several phosphatidylcholines (LPC(16:1), LPC(18:1), LPC(20:4), and PC(16:0/9:0(CHO))/PC (16:0/9:0(COH)), 2-keto-n-caproic acid/2-keto-isocaproic acid and N-methyl alanine increased, compared to baseline. The plasma decrease in taurocholic acid was associated with a reduction in Child-Turcotte-Pugh (CTP) (AMR-3.39; q-value=0.006) and liver stiffness measurement (LSM) (AMR-1.06; q-value<0.001), the plasma increase in LPC(20:4) was related to a reduction in LSM (AMR-0.98; q-value=0.027), and the rise of plasma 2-keto-n-caproic acid/2-keto-isocaproic acid was associated with a reduction in CTP (AMR-0.35; q-value=0.004). Finally, plasma changes in taurocholic acid were directly associated with inflammation-related biomarkers, while changes in LPC(20:4) were inversely associated. Conclusions: Plasma metabolomic profile changed after HCV clearance with all oral-DAAs in HIV/HCV-coinfected with advanced HCV-related cirrhosis. Changes in plasma levels of LPC (20: 4), 2-keto-n-caproic acid/2-keto-isocaproic acid, and taurocholic acid were related to improvements in cirrhosis scores and inflammatory status of patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting
    Londono, Maria-Carlota
    Manzardo, Christian
    Rimola, Antoni
    Ruiz, Pablo
    Costa, Josep
    Forner, Alejandro
    Ambrosioni, Juan
    Aguero, Fernando
    Laguno, Montserrat
    Lligona, Anna
    Moreno, Asuncion
    Miro, Jose-Maria
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (11) : 3195 - 3201
  • [22] Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status
    Garcia-Broncano, Pilar
    Maria Medrano, Luz
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Angeles Jimenez-Sousa, Ma
    Carrero, Ana
    Hontanon, Victor
    Guardiola, Josep M.
    Crespo, Manuel
    Quereda, Carmen
    Sanz, Jose
    Belen Garcia-Gomez, Ana
    Luis Jimenez, Jose
    Resino, Salvador
    CELLS, 2018, 7 (11)
  • [23] Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients
    Merli, Marco
    Galli, Laura
    Castagna, Antonella
    Salpietro, Stefania
    Gianotti, Nicola
    Messina, Emanuela
    Poli, Andrea
    Morsica, Giulia
    Bagaglio, Sabrina
    Cernuschi, Massimo
    Bigoloni, Alba
    Uberti-Foppa, Caterina
    Lazzarin, Adriano
    Hasson, Hamid
    NEW MICROBIOLOGICA, 2016, 39 (02) : 110 - 113
  • [24] Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response
    José Luis Casado
    María Angeles Esteban
    Sara Bañón
    Ana Moreno
    María J. Perez-Elías
    María Luisa Mateos
    Santiago Moreno
    Carmen Quereda
    Digestive Diseases and Sciences, 2015, 60 : 3473 - 3481
  • [25] Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
    Merchante, Nicolas
    Tellez, Francisco
    Rivero-Juarez, Antonio
    Jose Rios-Villegas, Maria
    Merino, Dolores
    Marquez-Solero, Manuel
    Omar, Mohamed
    Recio, Eva
    Perez-Perez, Montserrat
    Camacho, Angela
    Macias-Dorado, Sara
    Macias, Juan
    Lorenzo-Moncada, Sandra
    Rivero, Antonio
    Pineda, Juan A.
    BMC INFECTIOUS DISEASES, 2015, 15
  • [26] FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients
    Pineda-Tenor, Daniel
    Berenguer, Juan
    Jimenez-Sousa, Maria A.
    Garcia-Alvarez, Monica
    Aldamiz-Echevarria, Teresa
    Carrero, Ana
    Vazquez-Moron, Sonia
    Garcia-Broncano, Pilar
    Diez, Cristina
    Tejerina, Francisco
    Guzman-Fulgencio, Maria
    Resino, Salvador
    BMC MEDICINE, 2014, 12 : 198
  • [27] The Era of DAAs: Assessing the Patients' Characteristics, Clinical Impact, and Emergence of Comorbidities in HIV/HCV-Coinfected versus HIV-Infected Individuals
    Alvarez-alvarez, Beatriz
    Prieto-perez, Laura
    De La Cuadra-grande, Alberto
    Casado, Miguel Angel
    Ubeda, Alfonso Cabello
    Al-hayani, Aws W.
    Acosta, Irene Carrillo
    Mahillo-fernandez, Ignacio
    Hernandez-mora, Miguel Gorgolas
    Benito, Jose M.
    Rallon, Norma
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (13)
  • [28] Update on chronic hepatitis C in HIV/HCV-coinfected patients:: viral interactions and therapy
    Bräu, N
    AIDS, 2003, 17 (16) : 2279 - 2290
  • [29] HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
    Brochado-Kith, Oscar
    Martinez, Isidoro
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Salguero, Sergio
    Sepulveda-Crespo, Daniel
    Diez, Cristina
    Hontanon, Victor
    Ibanez-Samaniego, Luis
    Perez-Latorre, Leire
    Fernandez-Rodriguez, Amanda
    angeles Jimenez-Sousa, Maria
    Resino, Salvador
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [30] Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients
    Arenzana, Carmen Busca
    Gonzalez-Garcia, Juan
    Blas-Garcia, Ana
    V. Esplugues, Juan
    Martin, Antonio Olveira
    Ramirez, Maria Luisa Montes
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2024, 42 (02): : 74 - 79